Clinical Trial Update: Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) [Phase 3]

View source ↗

Summary

Phase III clinical trial update for TY-9591 in locally advanced or metastatic non-small cell lung cancer (NCT05382728) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TY-9591 (TY-9591)

Snippet

Sponsor: TYK Medicines, Inc | Conditions: NSCLC, EGFR Activating Mutation | Phase 3 | Status: RECRUITING